The strategic family Proven Longevity sits within. Cutting-edge therapeutics outside the mainstream pharma narrative — psychedelics, peptides, metabolic, hormonal, cannabis + botanicals, recovery. 22 compounds canvassed across three parallel research passes, 14 viable ventures identified. Read the Canvas brief first — it covers the brand architecture, viability rankings and priority sequencing. The two Bridge briefs detail specific ventures already at proposal stage.
In roadmap (briefs to follow): Proven Metabolic (GLP-1 branded affiliate) · Cannabis Compass UK (medical cannabis referral) · Proven Hormones (TRT) · Proven Psyche (ketamine telehealth aggregator) · 5-MeO + Ayahuasca Bridge · Proven Botanicals (kanna-led functional botanicals) · Methylene Blue Bridge · Cannabis Compass US. See the Canvas brief for full priority sequencing.